Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.

But her consultant, Medical Oncologist Dr Noor Tariq, gave her a ”glimmer of hope.” Rosslyn’s non-small-cell lung cancer had ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, ...

“Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.” ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.

KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...